EDP-305

EDP-305 is a potent, selective, non-bile acid farnesoid X receptor (FXR) agonist developed by Enanta Pharmaceuticals. It is being investigated primarily for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). FXR is a nuclear receptor that regulates bile acid levels in the liver and small intestine, influencing gene transcription related to lipid metabolism, insulin resistance, inflammation, and fibrosis. EDP-305 has been designed to enhance binding interactions with FXR while avoiding the carboxylic acid group found in other FXR agonists and natural bile acids. This design reduces the formation of taurine and glycine conjugates. Preclinical studies indicate that CYP3A4 is the main enzyme involved in its metabolism with low potential for drug-drug interactions[1][5][6][7][8].